Oncology · 2011 · 16 citations · 14 references
MedicineOncologyPharmacotherapyChemotherapyMetastasisTumor ProgressionBreast Cancer PharmacotherapyClinical Trial PhasesMetastatic Breast CancerMetastatic Cancer ManagementMetastatic Disease ManagementMetastatic Disease TreatmentBreast Cancer ChemotherapyCapecitabine-based TherapyChemotherapy Regimen DesignMetastatic Breast Cancer TreatmentRandomized Controlled Trial BaselineSample Size EstimationStudy Termination Criteria
OBJECTIVE: To assess the efficacy of capecitabine plus docetaxel (XT) versus epirubicin plus docetaxel (ET) as first-line therapy for metastatic breast cancer (MBC). PATIENTS AND METHODS: Patients with no prior chemotherapy for MBC were randomized to 3-weekly cycles of either XT (capecitabine 1,000 mg/m(2) twice daily, days 1-14; docetaxel 75 mg/m(2), day 1) or ET (epirubicin 75 mg/m(2), day 1; docetaxel 75 mg/m(2), day 1). The primary endpoint was non-progression rate 6 months after randomization. The planned sample size was 106 patients based on a randomized, phase II selection design. RESULTS: Between April 2004 and January 2007, 68 patients were randomized, giving 82% power to select the best regimen according to a 6-month non-progression rate. Slow accrual led to premature study termination. Baseline characteristics were generally well balanced between arms. The 6-month non-progression rates were 75.8% with XT versus 65.7% with ET (p = 0.36). After 42 months' median follow-up, median progression-free survival was 12.4 versus 6.8 months, respectively (p = 0.040). The safety profiles were consistent with previous experience. CONCLUSION: Further larger studies are warranted to validate these results. Despite more grade 3 hand-foot syndrome, first-line XT may be a valid alternative to ET, potentially improving efficacy.
14
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Kathy D. Miller, Molin Wang, Julie R. Gralow et al. · New England Journal of Medicine · 2007 · 3.1K citations · Full text
Medicine, Oncology, Pharmacology +13
Interpreting the significance of changes in health-related quality-of-life scores.
David Osoba, George Rodrigues, James D. Myles et al. · Journal of Clinical Oncology · 1998 · 2.9K citations
Joyce O’Shaughnessy, David Miles, Svetislava J. Vukelja et al. · Journal of Clinical Oncology · 2002 · 1.1K citations
Medicine, Oncology, Pharmacology +14
Nicholas J. Robert, Véronique Dièras, John A. Glaspy et al. · Journal of Clinical Oncology · 2011 · 1.1K citations
Medicine, Oncology, Pharmacotherapy +15
David Miles, Arlene Chan, Luc Dirix et al. · Journal of Clinical Oncology · 2010 · 887 citations
Medicine, Oncology, Pharmacology +17